Summary by Futu AI
Hepalink Pharmaceutical Holdings Limited (Hepalink Pharmaceuticals-B) submitted the next day disclosure report on September 23, 2024, disclosing its shareholding changes. The report shows that on September 23, 2024, the company repurchased 134,000 ordinary shares, accounting for 0.0174% of its issued shares, at a repurchase price ranging from HKD 1.19 to HKD 1.24, with a total repurchase price of HKD 163,740. The repurchased shares will be held as treasury shares. After the repurchase, the company's issued shares decreased to 767,922,410 shares, while treasury shares increased to 954,000 shares. The company confirmed that the share repurchase has been approved by the board of directors and complies with all applicable listing rules and legal requirements. The resolution authorizing the repurchase was passed on June 6, 2024, and the total number of shares the company may repurchase under the authorization is 76,887,641 shares. Under the rules, the company shall not issue new shares or sell or transfer any treasury shares within 30 days after the share repurchase.
